Adenovirus Specific T- Lymphocytes
Phase 2Biologic
Adenovirus Specific T- Lymphocytes is one of 7 biologic programs targeting Adenovirus. It is currently in Phase 2.
3
Indications
3
Total Trials
3
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Epstein Barr Virus
#DrugCompanyPhaseTrials
1Adenovirus Specific T- Lymphocytes
JJessie L. Alexander
Phase 2
Mrna-1189
ModernaPhase 2
EBV Gp350-Ferritin Vaccine
NNational Institute of Allergy and Infectious Diseases (NIAID)
Phase 2
Cytomegalovirus Specific T-Lymphocytes
JJessie L. Alexander
Phase 2
EBV MRNA Vaccine
WWest China Hospital
Phase 1
Matrix-M1 Adjuvant
NNovavax
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Adenovirus Infections1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- JJessie L. Alexander